Santen Pharmaceutical Co Stock Net Income
| SNPHFDelisted Stock | USD 11.45 0.00 0.00% |
As of the 18th of February 2026, Santen Pharmaceutical has the Coefficient Of Variation of 415.09, risk adjusted performance of 0.1936, and Variance of 0.9993. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Santen Pharmaceutical, as well as the relationship between them. Please validate Santen Pharmaceutical market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Santen Pharmaceutical is priced more or less accurately, providing market reflects its prevalent price of 11.45 per share. Given that Santen Pharmaceutical has total risk alpha of 0.1767, we advise you to double-check Santen Pharmaceutical Co's current market performance to make sure the company can sustain itself at a future point.
Santen Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Santen Pharmaceutical's valuation are provided below:Santen Pharmaceutical Co does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Santen |
Search Suggestions
| SNP | China Petroleum Chemical | CompanyDelisted |
| SNPW | Sun Pacific Holding | Company |
| SNPIX | Short Oil Gas | Mutual Fund |
| SNPD | DBX ETF Trust | ETF |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Santen Pharmaceutical Co reported net income of 27.22 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The net income for all United States stocks is significantly lower than that of the firm.
Santen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Santen Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Santen Pharmaceutical could also be used in its relative valuation, which is a method of valuing Santen Pharmaceutical by comparing valuation metrics of similar companies.Santen Pharmaceutical is currently under evaluation in net income category among its peers.
Santen Fundamentals
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 388.22 M | |||
| Shares Owned By Insiders | 3.21 % | |||
| Shares Owned By Institutions | 53.50 % | |||
| Price To Earning | 14.54 X | |||
| Price To Book | 1.39 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 266.26 B | |||
| Gross Profit | 156.59 B | |||
| EBITDA | 53.91 B | |||
| Net Income | 27.22 B | |||
| Cash And Equivalents | 69.53 B | |||
| Cash Per Share | 176.84 X | |||
| Total Debt | 32.93 B | |||
| Debt To Equity | 0.1 % | |||
| Current Ratio | 2.48 X | |||
| Book Value Per Share | 780.63 X | |||
| Cash Flow From Operations | 46.04 B | |||
| Earnings Per Share | 0.50 X | |||
| Price To Earnings To Growth | 20,399 X | |||
| Number Of Employees | 4.32 K | |||
| Beta | 0.38 | |||
| Market Capitalization | 2.95 B | |||
| Total Asset | 459.98 B | |||
| Retained Earnings | 230.22 B | |||
| Working Capital | 106.3 B | |||
| Current Asset | 156.63 B | |||
| Current Liabilities | 50.32 B | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 1.57 % | |||
| Net Asset | 459.98 B | |||
| Last Dividend Paid | 16.0 |
About Santen Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Santen Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Santen Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Santen Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Santen Pink Sheet
If you are still planning to invest in Santen Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Santen Pharmaceutical's history and understand the potential risks before investing.
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |